Shares of Illumina, Inc. (NASDAQ:ILMN) have received a consensus recommendation of “Hold” from the twenty-seven brokerages that are covering the firm. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $149.38.
ILMN has been the subject of a number of analyst reports. Citigroup Inc. upped their price target on Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Argus reaffirmed a “buy” rating and issued a $170.00 price objective (down previously from $205.00) on shares of Illumina in a research note on Friday, October 14th. Zacks Investment Research lowered Illumina from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 19th. Canaccord Genuity set a $136.00 price target on Illumina and gave the company a “hold” rating in a research note on Friday, October 7th. Finally, Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $154.48 price target for the company. in a research note on Wednesday, October 19th.
Illumina (NASDAQ:ILMN) opened at 128.04 on Wednesday. The firm has a 50-day moving average price of $130.35 and a 200 day moving average price of $150.40. The company has a market cap of $18.81 billion, a P/E ratio of 42.97 and a beta of 1.17. Illumina has a 52 week low of $119.37 and a 52 week high of $188.25.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.10. The company earned $607 million during the quarter, compared to analysts’ expectations of $628.06 million. Illumina had a return on equity of 23.76% and a net margin of 18.72%. Illumina’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 earnings per share. Analysts expect that Illumina will post $3.32 EPS for the current fiscal year.
In other Illumina news, Director Daniel Bradbury sold 600 shares of the stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total value of $110,616.00. Following the completion of the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at $3,146,103.40. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Omead Ostadan sold 2,000 shares of the stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $126.16, for a total transaction of $252,320.00. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Checchi Capital Advisers LLC boosted its position in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the period. Concert Wealth Management Inc. raised its stake in shares of Illumina by 2.9% in the third quarter. Concert Wealth Management Inc. now owns 1,732 shares of the life sciences company’s stock worth $315,000 after buying an additional 48 shares during the period. Mn Services Vermogensbeheer B.V. raised its stake in shares of Illumina by 2.0% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 3,771 shares of the life sciences company’s stock worth $685,000 after buying an additional 73 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of Illumina by 1.1% in the second quarter. Cullen Frost Bankers Inc. now owns 6,770 shares of the life sciences company’s stock worth $951,000 after buying an additional 75 shares during the period. Finally, Halsey Associates Inc. CT raised its stake in shares of Illumina by 0.7% in the second quarter. Halsey Associates Inc. CT now owns 12,510 shares of the life sciences company’s stock worth $1,756,000 after buying an additional 90 shares during the period. 92.92% of the stock is owned by institutional investors.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.